US2020222340A1PendingUtilityA1

Rapid dissolution formulation of a calcium receptor-active compound

Assignee: AMGEN INCPriority: Sep 12, 2003Filed: Mar 27, 2020Published: Jul 16, 2020
Est. expirySep 12, 2023(expired)· nominal 20-yr term from priority
A61K 31/135A61K 9/20A61K 9/2866A61P 3/14A61P 5/00A61P 5/20A61P 3/00A61K 9/2077A61P 5/18A61K 31/137A61K 31/00A61P 43/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising an effective dosage amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient,
 wherein at least one dosage unit of the composition has a dissolution profile in 0.05 N HCl, measured according to a dissolution test conducted in a USP 2 apparatus at a temperature of about 37° C., and at a rotation speed of about 75 r.p.m., which comprises from about 50% to about 125% of a target amount of the calcium receptor-active compound being released from the composition no later than about 30 minutes from the start of the test.   
     
     
         2 .- 118 . (canceled)

Join the waitlist — get patent alerts

Track US2020222340A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.